Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
Pharmacology, Toxicology and Pharmaceutical Science
8
2%
Other
48
13%
Unknown
180
49%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 2057. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 September 2026.
All research outputs
#5,179
of 34,365,356 outputs
Outputs from The Lancet
#212
of 51,902 outputs
Outputs of similar age
#238
of 464,517 outputs
Outputs of similar age from The Lancet
#13
of 371 outputs
Altmetric has tracked 34,365,356 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 51,902 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 63.4. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 464,517 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 371 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.
